Apricus Biosciences Inc (NASDAQ:APRI) was the target of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 1,466,072 shares, an increase of 37.1% from the October 15th total of 1,069,321 shares. Approximately 6.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,756,040 shares, the days-to-cover ratio is currently 0.8 days.
Separately, ValuEngine upgraded Apricus Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, November 1st.
Shares of Apricus Biosciences stock opened at $0.34 on Friday. The firm has a market capitalization of $9.88 million, a PE ratio of -0.35 and a beta of 0.93. Apricus Biosciences has a fifty-two week low of $0.25 and a fifty-two week high of $3.34.
Apricus Biosciences (NASDAQ:APRI) last announced its quarterly earnings data on Wednesday, October 31st. The company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.02. Analysts forecast that Apricus Biosciences will post -0.4 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Apricus Biosciences Inc (APRI) Sees Large Increase in Short Interest” was originally published by Macon Daily and is owned by of Macon Daily. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://macondaily.com/2018/11/11/apricus-biosciences-inc-apri-sees-large-increase-in-short-interest.html.
Apricus Biosciences Company Profile
Apricus Biosciences, Inc, a biopharmaceutical company, focuses on the development of product candidates in the areas of urology and rheumatology. The company develops Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction; and RayVa, which is in Phase IIa clinical trial to treat Raynaud's phenomenon associated with scleroderma.
Featured Article: Why do companies issue stock splits?
Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.